Conecte-se

Bibliografias temáticas / SARS (Severe Acute Respiratory Syndrome)

Índice

Artigos de revistas
Teses / dissertações
Livros
Capítulos de livros
Trabalhos de conferências
Relatórios de organizações

Literatura científica selecionada sobre o tema "SARS (Severe Acute Respiratory Syndrome)"

Autor: Grafiati

Publicado: 29 de julho de 2024

Última modificação: 30 de julho de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "SARS (Severe Acute Respiratory Syndrome)".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Seguljev, Zorica. "Severe acute respiratory syndrome (SARS)". Medical review 57, n.º 1-2 (2004): 5–6. http://dx.doi.org/10.2298/mpns0402005s.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Woodhead, M., S. Ewig e A. Torres. "Severe acute respiratory syndrome (SARS)". European Respiratory Journal 21, n.º 5 (maio de 2003): 739–40. http://dx.doi.org/10.1183/09031936.03.00035403.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Wong, K. F., T. S. To e John K. C. Chan. "Severe acute respiratory syndrome (SARS)". British Journal of Haematology 122, n.º 2 (julho de 2003): 171. http://dx.doi.org/10.1046/j.1365-2141.2003.04513.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Ngan Kee, Warwick D., e Tse N. Leung. "Severe acute respiratory syndrome (SARS)". International Journal of Obstetric Anesthesia 12, n.º 3 (julho de 2003): 151–52. http://dx.doi.org/10.1016/s0959-289x(03)00061-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Peiris, J. S. M. "Severe Acute Respiratory Syndrome (SARS)". Journal of Clinical Virology 28, n.º 3 (dezembro de 2003): 245–47. http://dx.doi.org/10.1016/j.jcv.2003.08.005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Bhaskar, G., Rakesh Lodha e S. K. Kabra. "Severe acute respiratory syndrome (SARS)". Indian Journal of Pediatrics 70, n.º 5 (maio de 2003): 401–5. http://dx.doi.org/10.1007/bf02723614.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Kawana, Akihiko. "Severe Acute Respiratory Syndrome (SARS)". Journal of Disaster Research 6, n.º 4 (1 de agosto de 2011): 404–12. http://dx.doi.org/10.20965/jdr.2011.p0404.

Texto completo da fonte

Resumo:

Severe acute respiratory syndrome, or SARS, was the first emerging infection of the 21stcentury. Severe pneumonia is the main symptom, and the case fatality rate was about 10%. In general, convalescence becomes less satisfactory with the age of the patient. The older the patient is, the more unsatisfactorily his or her convalescence is. The disease is transmitted mainly through the spread of droplets from the human respiratory tract. Many health care professionals became infected with SARS within the medical facilities in which they worked. No peculiar medicine or vaccine for SARS has yet been developed. A worldwide epidemic of SARS centered in China broke out around during the period from 2002 to 2003; about 8,000 cases were recorded. Although this epidemic has come to an end, attention should be paid to SARS because of its possible reemergence. Preparedness for SARS can be also applied to measures against other emerging infections.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Muller, N. L. "Severe acute respiratory syndrome (SARS)". Thorax 58, n.º 11 (1 de novembro de 2003): 919. http://dx.doi.org/10.1136/thorax.58.11.919.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Cameron, Peter A., e Timothy H. Rainer. "Severe acute respiratory syndrome (SARS)". Emergency Medicine Australasia 15, n.º 5-6 (outubro de 2003): 413–17. http://dx.doi.org/10.1046/j.1442-2026.2003.00494.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Cleri, Dennis J., Anthony J. Ricketti e John R. Vernaleo. "Severe Acute Respiratory Syndrome (SARS)". Infectious Disease Clinics of North America 24, n.º 1 (março de 2010): 175–202. http://dx.doi.org/10.1016/j.idc.2009.10.005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Teses / dissertações sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Chu, Chung-ming. "Clinical aspects of severe acute respiratory syndrome (SARS)". Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31937925.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Chu, Chung-ming, e 朱頌明. "Clinical aspects of severe acute respiratory syndrome (SARS)". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B31937925.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Lau, Yik-Chung. "Numerical simulation of severe acute respiratory syndrome (SARS) epidemics /". View abstract or full-text, 2004. http://library.ust.hk/cgi/db/thesis.pl?PHYS%202004%20LAU.

Texto completo da fonte

Resumo:

Thesis (M. Phil.)--Hong Kong University of Science and Technology, 2004.
Includes bibliographical references (leaves 43-44). Also available in electronic version. Access restricted to campus users.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Chauhan, Vinita Singh. "Molecular characterization of severe acute respiratory syndrome (SARS) coronavirus - nucleocapsid protein". Diss., Manhattan, Kan. : Kansas State University, 2006. http://hdl.handle.net/2097/152.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Ching, Chi-yun Johannes. "Study of host genetic susceptibility to severe acute respiratory syndrome (SARS) infection". Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40687648.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Ching, Chi-yun Johannes, e 程子忻. "Study of host genetic susceptibility to severe acute respiratory syndrome (SARS) infection". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B40687648.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Chow, Yan-ching Ken, e 周恩正. "Characterization of the apoptotic properties of severe acute respiratory syndrome coronavirus (SARS-CoV) structural proteins". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B30105493.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Ng, Yuen-yi Fiona. "Assessment of quality of life in adults recovering from severe acute respiratory syndrome /". Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972998.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Leung, Hiu-lan Nancy, e 梁曉灡. "Mechanism of antibody-dependent enhancement in severe acute respiratory syndrome coronavirus infection". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B47327066.

Texto completo da fonte

Resumo:

Severe lymphopenia is a clinical feature of Severe Acute Respiratory Syndrome (SARS) patients. However, lymphocytes do not express receptor for SARS-CoV, neither the widely accepted viral receptor angiotensin converting enzyme 2 (ACE2) nor the putative receptors Dendritic Cell- and Liver/lymph-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN and L-SIGN). Our group previously showed in vitro that, SARS-CoV Spike pseudotyped particles (SARSCoVpp) could infect human B cells only when inoculated in presence of anti-SARSCoV Spike immune serum. Such observations raised concerns about the possible occurrence of antibody-dependent enhancement (ADE) of infection, a phenomenon during which a virus bounded by antibodies could gain entry into cells through mechanisms involving complement receptors or Fc receptors. Recently, we have demonstrated the participation of the human Fc gamma receptor II (hFcγRII) molecules in granting SARS-CoV an opportunity to infect human immune cells. The aim of this study was to decipher the molecular mechanism leading to antibodymediated, FcγRII-dependent infection of immune cells by SARS-CoV. By using transduction experiment, I highlighted that different members of the hFcγRII family (namely hFcγRIIA, hFcγRIIB1 and hFcγRIIB2) could confer susceptibility to ADE of SARS-CoVpp infection. I further demonstrated that purified anti-viral immunoglobulin G, but not other soluble factor(s) from heat-inactivated immune serum, was the determinant for occurrence of ADE infection. Additionally, with the development of a cell-cell fusion assay, I illustrated that in contrast to the ACE2- dependent pathway, ADE infection did not occur at the plasma membrane, but rather require internalization of virus/antibodies immune complexes by the target cells. In line with this hypothesis, my results using a panel of FcγRII-expressing mutants demonstrated that binding of immune complexes to cell surface FcγRII was a prerequisite but was not sufficient to trigger ADE infection. In these experiments, only FcγRII signaling-competent constructions conferred susceptibility to ADE of SARS-CoVpp infection. Altogether my results point toward a role of the anti-SARS-CoV Spike IgG in vitro in granting SARS-CoV an opportunity to infect cells bearing signaling-competent FcγRII receptors. If further confirmed, such observations could have implications for understanding SARS-CoV tropism and SARS pathogenesis, as well as warrant for careful design of SARS vaccines and immunotherapy based on anti-viral antibodies.
published_or_final_version
Microbiology
Master
Master of Philosophy

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Xu, Meishu. "Association of DC-SIGN (CD209) gene polymorphisms with severe acute respiratory syndrome (SARS)". View the Table of Contents & Abstract, 2007. http://sunzi.lib.hku.hk/hkuto/record/B3723125X.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Livros sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Okeyo, T. M. Family education handbook on SARS, Severe Acute Respiratory Syndrome. Nairobi: Centre for Quality in Healthcare Organization, 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

S, Griffen Ashley, ed. Progress in SARS research. Hauppauge, NY: Nova Science Publishers, 2005.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Sujudi, Achmad. Menangkal badai: Pengalaman mencegah ancaman severe acute respiratory syndrome (SARS) tahun 2003. Jakarta: Departemen Kesehatan R.I., 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Serradell, Joaquima. SARS. 2^a ed. New York: Chelsea House, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Serradell, Joaquima. SARS. Editado por Babcock Hilary. 2^a ed. New York: Chelsea House, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Serradell, Joaquima. SARS. Editado por Babcock Hilary. 2^a ed. New York: Chelsea House, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Severe acute respiratory syndrome (SARS): Hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, first session on examining the status of the severe acute respiratory syndrome threat, April 29, 2003. Washington: U.S. G.P.O., 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Arthur, Kleinman, e Watson James L, eds. SARS in China: Prelude to pandemic? Stanford, Calif: Stanford University Press, 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Koh, Tommy T. B. 1937-, Plant Aileen J e Lee Eng Hin 1947-, eds. The new global threat: Severe acute respiratory syndrome and its impacts. Singapore: World Scientific, 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

1939-, Wong John, e Zheng Yongnian, eds. The SARS epidemic: Challenges to China's crisis management. Singapore: World Scientific, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Capítulos de livros sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Leung, CW. "SARS in Children". In Severe Acute Respiratory Syndrome, 30–35. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch4.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Ooi, Clara GC. "Radiology of SARS". In Severe Acute Respiratory Syndrome, 42–49. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Peiris, Malik, e Albert DME Osterhaus. "Aetiology of SARS". In Severe Acute Respiratory Syndrome, 50–57. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Heymann, David L. "SARS: A Global Perspective". In Severe Acute Respiratory Syndrome, 13–20. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Hayden, Frederick G., e Mark R. Denison. "Antiviral Agents for SARS". In Severe Acute Respiratory Syndrome, 184–202. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch20.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Drosten, C., KH Chan e LLM Poon. "Viral Diagnosis of SARS". In Severe Acute Respiratory Syndrome, 64–71. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Guan, Yi, Hume Field, Gavin JD Smith e Honglin Chen. "SARS Coronavirus: An Animal Reservoir?" In Severe Acute Respiratory Syndrome, 79–83. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch11.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Merianos, Angela, Robert Condon, Hitoshi Oshitani, Denise Werker e Roberta Andraghetti. "Epidemiology and Transmission of SARS". In Severe Acute Respiratory Syndrome, 100–110. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch13.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Wong, YC Richard, e Alan Siu. "Counting the Economic Cost of SARS". In Severe Acute Respiratory Syndrome, 213–30. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch22.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Hui, David S., e Kenneth W. Tsang. "SARS: Sequelae and Implications for Rehabilitation". In Severe Acute Respiratory Syndrome, 36–41. Oxford, UK: Blackwell Publishing Ltd, 2008. http://dx.doi.org/10.1002/9780470755952.ch5.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Huang, Yuxia. "Modeling the severe acute respiratory syndrome (SARS) outbreak in Beijing". In the 1st International Conference and Exhibition. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1823854.1823895.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Legband, Nathan, Jameel Feshitan, Mark Borden e Benjamin Terry. "Living Without Breathing: A Study in Extrapulmonary Respiration Using a Novel Oxygen Carrier". In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14735.

Texto completo da fonte

Resumo:

Pulmonary failure results when the lungs experience significant damage and are unable to supply the body and brain with oxygen. Pulmonary failure has many causes including lung cancer, physical trauma, acute respiratory distress syndrome (ARDS), aerosolized bioterrorism agents and diseases such as severe acute respiratory syndrome (SARS), pneumonia, and tuberculosis [1,2].

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

BURIOT, DIEGO. "HEALTH AND SECURITY SEVERE ACUTE RESPIRATORY SYNDROME (SARS): TAKING A NEW THREAT SERIOUSLY". In Fourth Centenary of the Foundation of the First Academy of Sciences: “Academia Lynceorum” by Federico Cesi and Pope Clemente VIII. WORLD SCIENTIFIC, 2004. http://dx.doi.org/10.1142/9789812702753_0023.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Amorim, Maria Clara Carvalho Silva de, Karla Oliveira Couto, Pedro José da Silva Júnior, Thiago Gonçalves Fukuda, Pedro Antônio Pereira de Jesus e Mateus Santana do Rosário. "Hemisferic encephalic involviment associated with sars- cov-2". In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.005.

Texto completo da fonte

Resumo:

Context: The novel severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) emerged in Wuhan, China and rapidly spread worldwide. Although the predominant clinical presentation is with respiratory disease, neurological manifestations are being recognised increasingly. Case report: In this report, we demonstrate a case of hemispheric brain in volvement as a neurological manifestation of Sars-cov-2 in a 74-year-old patient admitted to Hospital Santa Izabel (HSI) between May and July 2020. Conclusion: In COVID-19, although the predominant clinical presentation is with respiratory disease, neurological complications have been reported. Severe neurological complications are either because of direct viral invasion, immunological reaction, or hypoxic metabolic changes. The patients with encephalitis are usually severely or critically ill.

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Quinn, R., M. Liu, Y. Gu, T. Mak e E. Belden. "Keynote Lecture “Anti-viral Drug Discovery for Severe Acute Respiratory Syndrome (SARS-CoV-2)”". In GA – 70th Annual Meeting 2022. Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1758917.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Lazarus, Theophilus. "SARS-CoV-2 infection and neuropsychological outcomes". In 2nd International Neuropsychological Summer School named after A. R. Luria “The World After the Pandemic: Challenges and Prospects for Neuroscience”. Ural University Press, 2020. http://dx.doi.org/10.15826/b978-5-7996-3073-7.10.

Texto completo da fonte

Resumo:

The entire world is currently confronted with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS.CoV.2), a novel betacoronavirus causing the deadly pandemic of coronavirus disease 2019 (COVID.19). Since there is now increasing reports of neurological and cognitive problems, the impact of COVID.19 on neuropsychological functioning is unknown but is likely to leave residual problems.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Bezerra, Arthur Andrade, Davi Henrique dos Santos e Luiz Marcos Garcia Gonçalves. "Real-time Air Quality Monitoring Using Optical Sensors to Prevent Severe Acute Respiratory Syndromes (SARS)". In Latin America Optics and Photonics Conference. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/laop.2022.m2c.5.

Texto completo da fonte

Resumo:

This work presents the development, test, and validation of a system that gathers and analyses data from optical sensors to monitor the air quality of indoor environments to help prevent Severe Acute Respiratory Syndromes (SARS).

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Redondo Galán, C., M. Ferris Villanueva, D. González Vaquero, MD Rivas Rodríguez e JF Rangel Mayoral. "5PSQ-172 Experience with tocilizumab in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection". In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.291.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Sidorova, A. P., e A. V. Bakunovich. "ANTIRETROVIRAL DRUGS AS POTENTIAL INHIBITORS OF SARS-COV-2 Mpro". In SAKHAROV READINGS 2022: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-2-31-34.

Texto completo da fonte

Resumo:

Ritonavir, nelfinavir and lopinavir are a group of protease inhibitors. These inhibitors are widely used in combination with other protease inhibitors in the therapy and prevention of human immunodeficiency virus. Also, the combination of these inhibitors seems to be an effective therapeutic agent that can affect the main protease of Mpro coronavirus and, thus, provide long-term suppression of viral load in the disease of severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2).

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Bezerra, Arthur Andrade, Davi H. dos Santos e Luiz M. G. Gonçalves. "Real-Time Air Quality Monitoring Using Sensors to Prevent Severe Acute Respiratory Syndromes (SARS)". In Anais Estendidos da Conference on Graphics, Patterns and Images. Sociedade Brasileira de Computação - SBC, 2022. http://dx.doi.org/10.5753/sibgrapi.est.2022.23281.

Texto completo da fonte

Resumo:

This work presents the development, calibration, and validation of a device capable of actively capturing data related to the measurement of air quality for future prevention. This data can then be compared with pandemic/endemic data indices by location using PM2.5, temperature, and humidity sensors, along with a microcontroller capable of sending all necessary information to a database. As it is a project that needs a large scale so that it is possible to capture air quality indices in as many points as possible in order to obtain data with very high granularity, the development is always being thought of, always viewing the cost-effectiveness of the components used for replicating is possible, and also the development is part of a larger project, which should provide the community with a complete platform capable of providing real-time air quality data.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Relatórios de organizações sobre o assunto "SARS (Severe Acute Respiratory Syndrome)"

1

Fuller, Julie, Keith Hanley, Robert Schultz, Michael Lewis, Nicole Freed, Michael Ellis, Viseth Ngauy, Richard Stoebner, Margaret Ryan e Kevin Russel. Surveillance for Respiratory Infections, Including Severe Acute Respiratory, Syndrome (SARS), in Cobra Gold 2003. Fort Belvoir, VA: Defense Technical Information Center, maio de 2004. http://dx.doi.org/10.21236/ada455915.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Goren, Talia, Itai Beeri e Dana Rachel vashdi. Trust in government and compliance with health instructions during respiratory epidemics and pandemics: A systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, outubro de 2021. http://dx.doi.org/10.37766/inplasy2021.10.0041.

Texto completo da fonte

Resumo:

Review question / Objective: We will use the Condition-Context-Population (CoCoPop) framework (Munn et al., 2015) in this review, which aims to explore the following question: Do the features of respiratory epidemics and pandemics (e.g., magnitude, duration) impact the associations between (types of) trust in government and compliance with health guidelines? Condition being studied: The association between trust in government and authorities and civic compliance with health guidelines during respiratory epidemics and pandemics. Eligibility criteria: 1. Studies that explore the relationship between trust in government and authorities and civic compliance or compliance intentions with real or simulated health guidelines, during respiratory epidemics and pandemics; 2. Studies that focus on the following pandemics: avian influenza (H5N1), swine influenza (H1N1), Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS) and COVID-19; 3. Studies on the general healthy population (excluding health care professionals) 4. Studies that were published since 2002 to present.

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Moza, Andreea, Florentina Duica, Panagiotis Antoniadis, Elena Silvia Bernad, Diana Lungeanu, Marius Craina, Brenda Cristiana Bernad et al. Outcome of newborns in case of SARS-CoV-2 vertical infection. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, dezembro de 2022. http://dx.doi.org/10.37766/inplasy2022.12.0093.

Texto completo da fonte

Resumo:

Review question / Objective: To identify the types and examine the range of available evidence of vertical transmission of SARS-CoV-2 from mother to newborn. To clarify the key concepts and criteria for diagnosis of SARS-CoV-2 vertical infection in neonates. To summarize the existing evidence and advance the awareness on SARS-CoV-2 vertical infection in pregnancy. Background: Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2), the virus that causes 2019 coronavirus disease (COVID-19), has been isolated from various tissues and body fluids, including the placenta, amniotic fluid, and umbilical cord of newborns. In the last few years, much scientific effort has been directed towards studying SARS-CoV-2, focusing on the different features of the virus, such as its structure and mechanisms of action. Moreover, much focus has been on developing accurate diagnostic tools and various drugs or vaccines to treat COVID-19.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Kintz, Erica, Erin Lewis e Victoria Cohen. Qualitative assessment of the risk of SARS-CoV-2 to human health through food exposures to deer in the UK. Food Standards Agency, março de 2023. http://dx.doi.org/10.46756/sci.fsa.jip603.

Texto completo da fonte

Resumo:

SARS-CoV-2, the coronavirus responsible for the infectious disease COVID-19 (Gorbalenya et al 2020 (Opens in a new window)), was first detected in the human population in December 2019 (Zhu et al 2020 (Opens in a new window)). It has since spread to become a global pandemic. Previously, two other novel coronaviruses caused illness in the human population. The first, SARS-CoV (for Severe Acute Respiratory Syndrome) was recognised as a new illness in 2004 and the second, MERS-CoV (for Middle East respiratory syndrome) in 2012 (de Wit et al. 2016). These previous coronavirus outbreaks in humans occurred after bat coronaviruses passed through intermediate hosts (civet cats and camels, respectively) and then transmitted to infect humans (de Wit et al. 2016). SARS-CoV-2 infections in companion animals such as dogs, cats and ferrets and also in captive or farmed animals such as tigers and mink have been observed, likely as spill over events from contact with infected humans (WOAH 2022). There is now a large body of evidence from the United States that SARS-CoV-2 is capable of infecting white-tailed deer and that it can then spread further in the deer population (details in “What is the risk of SARS-CoV-2 being introduced into the cervid population in Great Britain?” (Defra, 2022). Assuming a worst-case scenario where SARS-CoV-2 is circulating within the UK deer population, this risk assessment was performed to determine whether handling and/or consuming UK-produced deer meat and/or offal may pose a risk of contracting SARS-CoV-2 in humans.

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Coronel-Monje, Katiusca, Mayron Antonio Candia-Puma, Juan Jeferson Vilca-Alosilla, Luis Daniel Goyzueta-Mamani, Herbert Mishaelf Aguilar Bravo, Jorge Augusto Sánchez Zegarra, Haruna Luz Barazorda-Ccahuana, Eduardo Antonio Ferraz Coelho e Miguel Angel Chávez-Fumagalli. A Systematic Review of Peruvian Contributions to Scientific Publications on Experimental Research Against COVID-19. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, abril de 2023. http://dx.doi.org/10.37766/inplasy2023.4.0080.

Texto completo da fonte

Resumo:

Review question / Objective: The objective of this research work is to evaluate the generation capacity of experimental research carried out in Peru, which will help in making future decisions, both to establish future studies, to elucidate the lack of studies in certain areas, as well as to determine the country's roadmap in a current and future state of emergency. Condition being studied: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 in Wuhan, China, and has spread worldwide becoming a pandemic with catastrophic effects. SARS-CoV-2 severely affects humans because it is highly transmissible and rapidly mutating, and is reported to have a mortality rate between 0.8-19.6% with regional variation. Various health strategies have been applied around the world, such as non-pharmacological interventions (use of masks, social distancing, monitoring of infected persons, etc.) and vaccination to reduce the spread of the virus and contagion. However, since the emergence of SARS-CoV-2, there have been approximately 755 million cases of COVID-19 and 6.8 million deaths by February 2023.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Wang, Xiao, Hong Shen, Yujie Liang, Yixin Wang, Meiqi Zhang e Hongtao Ma. Effects of physical activity interventions for post-COVID-19 patients: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, maio de 2022. http://dx.doi.org/10.37766/inplasy2022.5.0036.

Texto completo da fonte

Resumo:

Review question / Objective: Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused a huge impact in many countries and has attracted great attention from countries around the world. However, since the outbreak of the COVID-19 pandemic, most attention has focused on containing transmission and addressing the surge of critically ill patients in acute care settings. As we enter the second phase of the pandemic, emphasis must evolve to post care of COVID-19 survivors. A variety of persistent symptoms, such as severe fatigue, shortness of breath, and attention disorder have been reported at several months after the onset of the infection. We urgently need to identify safe and effective COVID-19 rehabilitative strategies. Overwhelming evidence exists that physical activity produces short-, middle- and long-term health benefits that prevent, delay, mitigate and even reverse a large number of metabolic, pulmonary and cardiovascular diseases. The purpose of this study was to evaluate the effects of physical activity interventions for rehabilitation of post-covid-19 patient and provide a reliable method and credible evidence to improve the prognosis of post-COVID-19 patients via systematic review and meta-analysis.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Şeker, Muzaffer, Ali Özer, Zekeriya Tosun, Cem Korkut e Mürsel Doğrul, eds. The Assessment Report on COVID-19 Global Outbreak. Türkiye Bilimler Akademisi, junho de 2020. http://dx.doi.org/10.53478/tuba.2020.119.

Texto completo da fonte

Resumo:

"In late December 2019, a large number of patients with unknown causes of pneumonia were reported by press from a seafood market in Wuhan, Hubei province, China. This coronavirus was originally named the 2019 new coronavirus (2019-nCoV) by the World Health Organization (WHO) on January 12, 2020. The Coronavirus Working Group (CSG) of the WHO and International Committee proposed to call the new virus SARS-CoV-2 on February 11, 2020. As a result of the samples taken from the patient, the whole genome sequence of the SARS-CoV-2 was isolated on January 7, 2020, by Chinese scientists in a short time. WHO announced on February 11, 2020; that “COVID-19” will become the official name of the disease. Tedros Adhanom Ghebreyesus, director of the WHO, said the epidemic meant “ko”, “corona”, “vi” for “virus” and “d” for “disease” as first described on December 31, 2019. Such a name has been preferred to avoid stigmatizing a particular region, animal species or human. The infection, which started to spread first in China and then in nearby countries, spread to most countries later on. The epidemic soon reached an international dimension, affecting the whole world. As a result, the WHO considered COVID-19 as an international public health problem and declared it as a pandemic on January 30, 2020. In humans, coronaviruses cause some cases of colds and respiratory infections that can be fatal, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus disease 2019 (COVID-19). In recent years, new viral infections have been detected periodically in various countries. The first epidemic; was observed in 2002-2003 as a result of the crossing of a new coronavirus from bat origin to humans through palm civet cats in Guangdong Province, China. This virus, called SARS, affected a total of 8422 people in China and caused 916 deaths (11% mortality, however different rates are given in different literatures). The second epidemic event occurred approximately 10 years later. In 2012, the MERS coronavirus (MERS-CoV) emerged from bat origin through a dromedary camel in Saudi Arabia. It affected a total of 2494 people and caused 858 deaths (mortality rate of 34%). WHO has declared it as a pandemic after the outbreak and scientists are doing great efforts to identify the characterization of the new coronavirus and to develop antiviral therapies and vaccines. Clinical studies and vaccination studies are still ongoing fastly. Also, the pathogenesis of the virus is still not fully known, and new studies are needed in this regard. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2. The most appropriate prophylactic regimen for patients under observation due to COVID-19 related disease is unknown. For this reason, treatment protocols should be planned by following the current guidelines. This study consists of evaluating the opinions about the history of pandemics associated with COVID-19, related definitions and the projects being carried out with the compilation of available resources, the development stages of the pandemic and the projection of postpandemic interaction so far."

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Şeker, Muzaffer, Ali Özer, Zekeriya Tosun, Cem Korkut e Mürsel Doğrul, eds. COVID-19 Küresel Salgın Değerlendirme Raporu. Türkiye Bilimler Akademisi, junho de 2020. http://dx.doi.org/10.53478/tuba.2020.118.

Texto completo da fonte

Resumo:

"In late December 2019, a large number of patients with unknown causes of pneumonia were reported by press from a seafood market in Wuhan, Hubei province, China. This coronavirus was originally named the 2019 new coronavirus (2019-nCoV) by the World Health Organization (WHO) on January 12, 2020. The Coronavirus Working Group (CSG) of the WHO and Internati- onal Committee proposed to call the new virus SARS-CoV-2 on February 11, 2020. As a result of the samples taken from the patient, the whole genome sequence of the SARS-CoV-2 was isolated on January 7, 2020, by Chinese scientists in a short time. WHO announced on Febru- ary 11, 2020; that “COVID-19” will become the official name of the disease. Tedros Adhanom Ghebreyesus, director of the WHO, said the epidemic meant “ko”, “corona”, “vi” for “virus” and “d” for “disease” as first described on December 31, 2019. Such a name has been preferred to avoid stigmatizing a particular region, animal species or human. The infection, which started to spread first in China and then in nearby countries, spread to most countries later on. The epidemic soon reached an international dimension, affecting the whole world. As a result, the WHO considered COVID-19 as an international public health problem and declared it as a pandemic on January 30, 2020. In humans, coronaviruses cause some cases of colds and respiratory infections that can be fatal, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus disease 2019 (COVID-19). In recent years, new viral infections have been detected periodically in various countries. The first epidemic; was observed in 2002-2003 as a result of the crossing of a new coronavirus from bat origin to humans through palm civet cats in Guangdong Province, China. This virus, called SARS, affected a total of 8422 people in China and caused 916 deaths (11% mortality, however different rates are given in different literatures). The second epidemic event occurred approximately 10 years later. In 2012, the MERS coronavirus (MERS-CoV) emerged from bat origin through a dromedary camel in Saudi Arabia. It affected a total of 2494 people and caused 858 deaths (mortality rate of 34%). WHO has declared it as a pandemic after the outbreak and scientists are doing great efforts to identify the characterization of the new coronavirus and to develop antiviral therapies and vaccines. Clinical studies and vaccination studies are still ongo- ing fastly. Also, the pathogenesis of the virus is still not fully known, and new studies are needed in this regard. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2. The most appropriate prophylactic regimen for patients under observa- tion due to COVID-19 related disease is unknown. For this reason, treatment protocols should be planned by following the current guidelines. This study consists of evaluating the opinions about the history of pandemics associated with COVID-19, related definitions and the projects being carried out with the compilation of avai- lable resources, the development stages of the pandemic and the projection of postpandemic interaction."

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Jenkins, J. Lee, Edbert B. Hsu, Anna Russell, Allen Zhang, Lisa M. Wilson e Eric B. Bass. Infection Prevention and Control for the Emergency Medical Services and 911 Workforce. Agency for Healthcare Research and Quality (AHRQ), novembro de 2022. http://dx.doi.org/10.23970/ahrqepctb42.

Texto completo da fonte

Resumo:

Objectives. To summarize current evidence on exposures to infectious pathogens in the emergency medical services (EMS) and 911 workforce, and on practices for preventing, recognizing, and controlling occupationally acquired infectious diseases and related exposures in that workforce. Review methods. We obtained advice on how to answer four Guiding Questions by recruiting a panel of external experts on EMS clinicians, State-level EMS leadership, and programs relevant to EMS personnel, and by engaging representatives of professional societies in infectious diseases and emergency medicine. We searched PubMed®, Embase®, CINAHL®, and SCOPUS from January 2006 to March 2022 for relevant studies. We also searched for reports from State and Federal Government agencies or nongovernmental organizations interested in infection prevention and control in the EMS and 911 workforce. Results. Twenty-five observational studies reported on the epidemiology of infections in the EMS and 911 workforce. They did not report demographic differences except for a higher risk of hepatitis C in older workers and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in minorities. EMS clinicians certified/licensed in Advanced Life Support have a high risk for blood and fluid exposure, and EMS clinicians had a higher risk of hospitalization or death from SARS-CoV-2 than firefighters whose roles were not primarily related to medical care. Eleven observational studies reported on infection prevention and control practices (IPC), providing some evidence that hand hygiene, standard precautions, mandatory vaccine policies, and on-site vaccine clinics are effective. Research on IPC in EMS and 911 workers has increased significantly since the SARS-CoV-2 pandemic. Conclusions. Moderate evidence exists on the epidemiology of infections and effectiveness of IPC practices in EMS and 911 workers, including hand hygiene, standard precautions, mandatory vaccine policies, and vaccine clinics. Most evidence is observational, with widely varying methods, outcomes, and reporting. More research is needed on personal protective equipment effectiveness and vaccine acceptance, and better guidance is needed for research methods in the EMS and 911 worker setting.

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

F, Verdugo-Paiva, Izcovich A, Ragusa M e Rada G. Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol. Epistemonikos Interactive Evidence Synthesis, janeiro de 2024. http://dx.doi.org/10.30846/ies.4f3c02f030.

Texto completo da fonte

Resumo:

Objective To assess the efficacy and safety of lopinavir/ritonavir for the treatment of patients with COVID-19. Design This is the protocol of a living systematic review. Data sources We will conduct searches in the [https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d](L.OVE platform for COVID-19), a system that maps PICO questions to a repository maintained through regular searches in electronic databases, preprint servers, trial registries and other resources relevant to COVID-19. No date or language restrictions will be applied. Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question. We will include randomised trials evaluating the effect of lopinavir/ritonavir— as monotherapy or in combination with other drugs — versus placebo or no treatment in patients with COVID-19. Randomised trials evaluating lopinavir/ritonavir in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case no direct evidence from randomised trials is found, or if the direct evidence provides low- or very low-certainty for critical outcomes. Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates. Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media. PROSPERO Registration [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=179212](CRD42020179212) Keywords COVID-19, severe acute respiratory syndrome coronavirus 2, Coronavirus Infections, Systematic review, lopinavir, lopinavir/ritonavir, antivirals

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!